Kenvue Nicorette®* products added to World Health Organization’s tobacco cessation pre-qualification list

On Tuesday, July 2, the World Health Organization (WHO) releasedthe first ever clinical treatment guidelinesfor tobacco cessation for adults. The guidelines focus on helping the more than 750 million tobacco users who want to quit all forms of tobacco.

These new guidelines share that "combining pharmacotherapy with behavioural interventions significantly increases quitting success rates." Among the recommendations is Nicotine Replacement Therapy (NRT): using products - like Nicorette® patches, gums, lozenge and mouth sprays - for tobacco cessation.

Kenvue's Nicorette® gum and patch are the first nicotine replacement therapies (NRTs) to be added to the WHO's pre-qualification list, which assesses the quality, safety, and efficacy of medicinal products. The WHO's pre-qualification list is intended to guide UN agencies and other international organizations on the quality of medicines in high priority therapeutic areas, notably for supply to low-income countries. NRT lozenge, oral spray, patch, and gum are also included on the WHO Model List of Essential Medicines (EML).

Since October 2022, Kenvue has been an active member of the WHO's Tobacco Cessation Consortium. The Consortium is a group of partners in the private and public sectors (including Tech, Consumer Health/Pharma, and NGOs) to help people access essential cessation support and treatment to deal with tobacco dependence.

Kenvue and Nicorette® are committed to making smoking cessation support and treatment available to more people and we are proud to be a part of creating a world free from tobacco and nicotine.

Learn more here: https://www.who.int/publications/i/item/9789240096431

*Nicorette® is not marketed or sold by Kenvue in the United States.